1,2,5-thiadiazoles (including Hydrogenated) Patents (Class 548/134)
  • Publication number: 20150076418
    Abstract: The invention relates to novel conjugated polymers comprising in their backbone one or more divalent donor units, like for example benzo[1,2-b:4,5-b?]dithiophene-2,6-diyl (BDT), that are linked on both sides to an acceptor unit, to methods of preparing the polymers and educts or intermediates used in such preparation, to polymer blends, mixtures and formulations containing the polymers, to the use of the polymers, polymer blends, mixtures and formulations as semiconductors organic electronic (OE) devices, especially in organic photovoltaic (OPV) devices and organic photodetectors (OPD), and to OE, OPV and OPD devices comprising these polymers, polymer blends, mixtures or formulations.
    Type: Application
    Filed: February 15, 2013
    Publication date: March 19, 2015
    Applicant: MERCK PATENT GMBH
    Inventors: Nicolas Blouin, Amy Phillips, Lana Nanson, Steven Tierney, Toby Cull, Priti Tiwana, Stephane Berney, Miguel Carrasco-Orozco, Frank Egon Meyer
  • Publication number: 20140315961
    Abstract: Described herein are compounds of Formula (I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting arginine methyltransferase activity. Methods of using the compounds for treating arginine methyltransferase-mediated disorders are also described.
    Type: Application
    Filed: March 14, 2014
    Publication date: October 23, 2014
    Applicant: Epizyme, Inc.
    Inventors: Richard Chesworth, Lorna Helen Mitchell, Gideon Shapiro
  • Publication number: 20140275552
    Abstract: Photoactive compositions of matter, methods for their design and synthesis, and various applications of such compositions of matter are disclosed. Such photoactive compositions may, for example, include any one or more of the following: a core moiety; a primary electron donor moiety; an electron-withdrawing moiety; and an alkyl tail. Some photoactive compositions may further include multiple additional electron donor moieties, electron-withdrawing moieties, and alkyl tails. Applications of such photoactive compositions of matter may include use in photovoltaic cells (e.g., as a p- or n-type material of the active layer of some photovoltaic cells, or as a dye to be employed in other photovoltaic cells); batteries, field-effect transistors; and light-emitting diodes.
    Type: Application
    Filed: March 15, 2013
    Publication date: September 18, 2014
    Inventors: Michael D. Irwin, Jerred A. Chute, Robert D. Maher, III
  • Publication number: 20140221383
    Abstract: Compounds having the structures of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis: In the compounds of Formula I, B or R2 is a phenyl group which has an ortho aryl, heterocyclic, benzoheterocyclic or benzocycloalkyl substituent, and one other position on the 5-membered ring has an aromatic, heterocyclic, cycloalkyl, benzoheterocyclic or benzocycloalkyl substituent connected directly to the ring or attached to the ring through a —CH2—.
    Type: Application
    Filed: April 14, 2014
    Publication date: August 7, 2014
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Amjad Ali, Joann M. Napolitano, Qiaolin Deng, Zhijian Lu, Peter J. Sinclair, Gayle E. Hallet, Christopher F. Thompson, Nazia Quraishi, Cameron J. Smith, Julianne A. Hunt, Adrian A. Dowst, Yi-Heng Chen, Hong Li
  • Patent number: 8796256
    Abstract: The present invention relates to compounds of Formula (I), methods for preparing these compounds, compositions, intermediates and derivatives thereof and for treating a condition including but not limited to ankylosing spondylitis, artherosclerosis, arthritis (such as rheumatoid arthritis, infectious arthritis, childhood arthritis, psoriatic arthritis, reactive arthritis), bone-related diseases (including those related to bone formation), breast cancer (including those unresponsive to anti-estrogen therapy), cardiovascular disorders, cartilage-related disease (such as cartilage injury/loss, cartilage degeneration, and those related to cartilage formation), chondrodysplasia, chondrosarcoma, chronic back injury, chronic bronchitis, chronic inflammatory airway disease, chronic obstructive pulmonary disease, diabetes, disorders of energy homeostasis, gout, pseudogout, lipid disorders, metabolic syndrome, multiple myeloma, obesity, osteoarthritis, osteogenesis imperfecta, osteolytic bone metastasis, osteomalac
    Type: Grant
    Filed: May 24, 2011
    Date of Patent: August 5, 2014
    Assignee: Janssen Pharmaceutica NV
    Inventors: Gilles Bignan, Wing Cheung, Micheal Gaul, Hui Huang, Xun Li, Raymond Patch, Sharmila Patel, Mark Player, Guozhang Xu, Bao-Ping Zhao, Jian Liu
  • Publication number: 20140024636
    Abstract: Provided is a sulfamide derivative having an adamantyl group represented by the following Formula 1, or a pharmaceutically acceptable salt thereof. The sulfamide derivative suppresses the activity of 11?-hydroxysteroid dehydrogenase type 1 (11?-HSD1), and is useful in the treatment of various diseases that are mediated by 11?-HSD1.
    Type: Application
    Filed: March 30, 2012
    Publication date: January 23, 2014
    Applicant: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY
    Inventors: Ki Young Kim, Jin Hee Ahn, Seung Kyu Kang, Sang Dal Rhee, Myung Ae Bae, Sung Hoon Ahn, Hee Youn Kim, Won Hoon Jung, Nam Sook Kang
  • Patent number: 8580799
    Abstract: The present invention relates to hydroximoyl-heterocycle derivatives of formula (I) wherein T represents a substituted or non-substituted heterocyclyl group, Q represents a carbo or heterocyclic group, A represent a carbo or heterocyclic group or a carbo or hetero-polycylic group, and L1 represents various linking groups, their process of preparation, intermediate compounds for their preparation, their use as fungicide active agents, particularly in the form of fungicide compositions, and methods for the control of phytopathogenic fungi, notably of plants, using these compounds or compositions.
    Type: Grant
    Filed: December 8, 2009
    Date of Patent: November 12, 2013
    Assignee: Bayer Cropscience AG
    Inventors: Christian Beier, Jurgen Benting, David Bernier, Pierre-Yves Coqueron, Philippe Desbordes, Christophe Dubost, Stephanie Gary, Pierre Genix, Daniela Portz, Ulrike Wachendorff-Neumann
  • Patent number: 8575355
    Abstract: Described herein are D-?-A type sensitizers of the formula (I) or (II) having a novel central ?-conjugated unit di-thiazolyl-benzodiazole and dye-sensitized electrodes including a substrate having an electrically conductive surface, an oxide semiconductor film formed on the conductive surface, and the above sensitizer of formula (I) or (II), as specified above, supported on the film. A solar cell includes the above electrode, a counter electrode, and an electrolyte deposited there between. The sensitizers of formula (I) and (II) efficiently sensitize the semiconductor materials and show a high solar to electricity conversion efficiency.
    Type: Grant
    Filed: December 23, 2011
    Date of Patent: November 5, 2013
    Assignee: King Abdulaziz City for Science and Technology
    Inventors: Mohammad Rezaul Karim, Md. Akhtaruzzaman, Ashraful Islam, Abdulrahman M. Al-Ahmari
  • Patent number: 8519150
    Abstract: Provided are a ?-electron conjugated polymer having a constitutional unit represented by general formula (2) that is suitable as an electrochromic material that changes from a desired colored state to a decolored state, a new compound that is a raw material of the polymer, and a method for producing the polymer: wherein each X independently represents one selected from the group consisting of an oxygen atom, a sulfur atom, —NH—, and —NR1— (wherein R1 is an optionally substituted alkyl group having 1 to 20 carbon atoms or an optionally substituted aryl group having 6 to 20 carbon atoms); each Y independently represents an oxygen atom or a sulfur atom; each Z independently represents one selected from the group consisting of a hydrogen atom and optionally substituted organic groups having 1 to 20 carbon atoms, and W is one selected from the group consisting of an ethynylene group, an optionally substituted ethenylene group, optionally substituted arylene groups, and optionally substituted divalent heteroaromati
    Type: Grant
    Filed: October 16, 2009
    Date of Patent: August 27, 2013
    Assignee: Kuraray Co., Ltd.
    Inventors: Yoshirou Kondou, Kirihiro Nakano, Tomiaki Otake
  • Patent number: 8501946
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof: wherein A is hydrogen, C1-4alkyl, C3-6cycloalkyl, C1-3alkoxy, C1-3alkoxy C1-4alkyl, C1-2fluoroalkyl, halogen, NR6R7, optionally substituted heteroaryl (Het), or optionally substituted phenyl, and R1, R2, R3, R4, R5, R6 and R7 are as defined in the description. The compounds or salts are thought to modulate P2X7 receptor function and to be capable of antagonizing the effects of ATP at the P2X7 receptor. The invention also provides the use of the compound or salt in the treatment or prophylaxis of, for example, inflammatory pain, neuropathic pain, visceral pain, rheumatoid arthritis, osteoarthritis or neurodegenerative disorders.
    Type: Grant
    Filed: April 28, 2010
    Date of Patent: August 6, 2013
    Assignee: Glaxo Group Limited
    Inventors: David Kenneth Dean, Jorge Munoz-Muriedas, Mairi Sime, Jon Graham Anthony Steadman, Rachel Elizabeth Anne Thewlis, Giancarlo Trani, Daryl Simon Walter
  • Publication number: 20130160854
    Abstract: Described herein are D-?-A type sensitizers of the formula (I) or (II) having a novel central ?-conjugated unit di-thiazolyl-benzodiazole and dye-sensitized electrodes including a substrate having an electrically conductive surface, an oxide semiconductor film formed on the conductive surface, and the above sensitizer of formula (I) or (II), as specified above, supported on the film. A solar cell includes the above electrode, a counter electrode, and an electrolyte deposited there between. The sensitizers of formula (I) and (II) efficiently sensitize the semiconductor materials and show a high solar to electricity conversion efficiency.
    Type: Application
    Filed: December 23, 2011
    Publication date: June 27, 2013
    Applicant: KING ABDULAZIZ CITY FOR SCIENCE AND TECHNOLOGY
    Inventors: Mohammad Rezaul Karim, Md. Akhtaruzzaman, Ashraful Islam, Abdulrahman M. Al-Ahmari
  • Patent number: 8450351
    Abstract: The present invention is directed to N-hydroxyamidino compounds which are modulators of indoleamine 2,3-dioxygenase (IDO), as well as pharmaceutical compositions thereof and methods of use thereof relating to the treatment of cancer and other diseases.
    Type: Grant
    Filed: December 19, 2006
    Date of Patent: May 28, 2013
    Assignee: Incyte Corporation
    Inventors: Andrew P. Combs, Amy Takvorian, Wenyu Zhu, Richard B. Sparks
  • Publication number: 20130092912
    Abstract: The present invention provides, among other things, a copolymer comprising at least one donor monomer and at least one acceptor monomer. The polymer may optionally further comprise at least one additional comonomer. The polymers are useful as a charge-transport, semiconducting, electrochemical conducting, photoconducting, or light emitting material. Microelectronic devices comprising such polymers (e.g., as a heterojunction therein) are also described.
    Type: Application
    Filed: June 8, 2011
    Publication date: April 18, 2013
    Inventor: Wei You
  • Publication number: 20130045995
    Abstract: The present invention relates to hydroximoyl-heterocycle derivatives of formula (I) wherein Het represents a pyridyl or thiazolyl group, T represents a substituted or non-substituted heterocyclyl group, and X represents various substituents.
    Type: Application
    Filed: April 22, 2011
    Publication date: February 21, 2013
    Inventors: Christian Beier, Jurgen Benting, David Bernier, Pierre-Yves Coqueron, Philippe Desbordes, Christophe Dubost, Daniela Portz, Ulrike Wachendorff-Neumann
  • Publication number: 20130035346
    Abstract: The invention concerns a compound of the Formula (I), wherein Qa is heteroaryl and is substituted with halogeno; R1 and R2 are hydrogen; and Qb is phenyl or heteroaryl, and Qb may optionally bear 1 or 2 substituents selected from hydroxy, halogeno and (1-6C)alkyl, or a pharmaceutically-acceptable salt thereof; processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of diseases or medical conditions mediated by cytokines.
    Type: Application
    Filed: September 27, 2012
    Publication date: February 7, 2013
    Applicant: AstraZeneca AB
    Inventor: AstraZeneca AB
  • Publication number: 20120299474
    Abstract: Provided are a light emitting material comprising one or more tetraphenylethene (TPE) derivatives of formula (1a) with high thermal stability and high solid quantum yield efficiency, and an electroluminescent or light emitting device such as OLED comprising the same TPE derivatives and a method of preparing the same.
    Type: Application
    Filed: March 1, 2011
    Publication date: November 29, 2012
    Applicant: THE HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY
    Inventors: Benzhong Tang, Zujin Zhao, Ka Wai Jim, Wing Yip Lam, Shuming Chen, Hoi Sing Kwok
  • Patent number: 8288403
    Abstract: The invention relates to methods for the treatment of Alzheimer's disease, cerebral amyloid angiopathy, hereditary cerebral hemorrhage with amyloidosis, Dutch-type (HCHWA-D), multi-infarct dementia, dementia pugilistica and Down syndrome which comprise administering a therapeutically effective amount of a compound of formula I wherein R1, R2, R3, V, W, Y, and Z are as defined herein or a pharmaceutically active acid addition salt of such compounds. The invention also relates to a subgenus of such compounds and pharmaceutical compositions containing them, as well as methods for their manufacture.
    Type: Grant
    Filed: November 4, 2009
    Date of Patent: October 16, 2012
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Karlheinz Baumann, Erwin Goetschi, Synese Jolidon, Anja Limberg, Thomas Luebbers
  • Patent number: 8288371
    Abstract: Compounds of the formula are disclosed. The compounds are CCR1 antagonists which are useful for the treatment and prevention of inflammatory and autoimmune diseases. Other embodiments are also disclosed.
    Type: Grant
    Filed: October 3, 2008
    Date of Patent: October 16, 2012
    Assignee: Pharmacopeia, LLC
    Inventors: Vidyadhar M. Paradkar, Marc Brescia, Ray James, Jinqi Liu, Ruiyan Liu, James Robert Merritt, Michelle Morris, Michael J. Ohlmeyer, Chongwu Zhang, Rui Zhang
  • Publication number: 20120232237
    Abstract: Compounds of Formula (I): (formula (I)) where: X1 and X2 are the same or different and each is independently Cl, Br, I, a substituted or unsubstituted aryl group or a substituted or unsubstituted heteroaryl group; and, Y is O, S, Se, NR1, R1C—CR2 or R1C?CR2, wherein R1 and R2 are the same or different and are each independently H or an organic group, are useful as monomers to produce oligomers or polymers that are useful in organic electronic devices.
    Type: Application
    Filed: November 3, 2010
    Publication date: September 13, 2012
    Inventors: Zhao Li, Jianfu Ding, Jianping Lu, Ye Tao
  • Publication number: 20120205593
    Abstract: A polymer compound including a structural unit represented by formula (I) or a structural unit represented by formula (III) and a structural unit represented by formula (II) has high photoelectric conversion efficiency when used in an organic photoelectric conversion device. wherein Ar1 and Ar2 are the same or different and represent trivalent heterocyclic group; Z represents a divalent group; Y represents a divalent heterocyclic group; wherein Ar1 and Ar2 are the same or different and represent trivalent heterocyclic group; Z represents a divalent group; Y represents a divalent heterocyclic group; two Ar1s may be the same or different; two Ar2s may be the same or different; and two Z's may be the same or different. -D-??(II) wherein D represents an arylene group or a heteroarylene group having a fused ring, provided that a divalent heterocyclic group represented by Y is different from a group represented by D.
    Type: Application
    Filed: October 22, 2010
    Publication date: August 16, 2012
    Applicant: SUMITOMO CHEMICAL COMPANY, LIMITED
    Inventors: Kenichiro Ohya, Ken Yoshimura
  • Publication number: 20120195857
    Abstract: The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.
    Type: Application
    Filed: August 4, 2011
    Publication date: August 2, 2012
    Inventors: Makonen Belema, Pothukanuri Srinivasu, John A. Bender, Omar D. Lopez, Qi Chen, Richard A. Rampulla, Samayamunthula Venkata Satya Arun Kumar Gupta, Nicholas A. Meanwell
  • Publication number: 20120184518
    Abstract: Methods for the treatment and/or prevention of an inflammatory disease or disorder through administration of an inhibitor of a glutaminyl peptide cyclotransferase. Inflammatory diseases or disorders treated or prevented by methods disclosed herein include mild cognitive impairment (MCI), rheumatoid arthritis, atherosclerosis, restenosis, pancreatitis, sepsis and peritonitus. Further provided are respective diagnostic methods, assays and kits.
    Type: Application
    Filed: January 20, 2012
    Publication date: July 19, 2012
    Applicant: PROBIODRUG AG
    Inventors: Stephan Schilling, Holger Cynis, Torsten Hoffman, Hans-Ulrich Demuth
  • Publication number: 20120138865
    Abstract: The invention relates to novel phenanthro[1,10,9,8-c,d,e,f,g]carbazole polymers, methods and materials for their preparation, their use as semiconductors in organic electronic (OE) devices, and to OE devices comprising these polymers.
    Type: Application
    Filed: July 14, 2010
    Publication date: June 7, 2012
    Applicant: Merck Patent Gesellschaft Mit Beschrankter Haftung
    Inventors: Nicolas Blouin, William Mitchell, Changsheng Wang, Steven Tierney
  • Patent number: 8138182
    Abstract: The present invention relates to a diketohydrazine derivative of formula (I) and a pharmaceutically acceptable salt thereof (the symbols in the formula have the same meaning as described in the specification). The compound of formula (I) has an inhibitory activity against cysteine protease, and it is useful for the treatment of inflammatory diseases, immune diseases, ischemic diseases, respiratory diseases, circulatory diseases, blood diseases, neuronal diseases, hepatic or biliary diseases, osseous or articular diseases, metabolic diseases, etc. And the compound has inhibitory activity against elastase and it is also useful for the treatment of COPD (chronic obstacle pulmonary diseases).
    Type: Grant
    Filed: September 24, 2009
    Date of Patent: March 20, 2012
    Assignee: Ono Pharmaceutical Co., Ltd.
    Inventors: Akira Hatayama, Hiroshi Tsuruta, Yasuo Ochi, Haruo Imawaka, Kazuyuki Ohmoto
  • Publication number: 20120004243
    Abstract: The invention concerns a compound of the Formula (I), wherein Qa is heteroaryl and is substituted with halogeno; R1 and R2 are hydrogen; and Qb is phenyl or heteroaryl, and Qb may optionally bear 1 or 2 substituents selected from hydroxy, halogeno and (1-6C)alkyl, or a pharmaceutically-acceptable salt thereof; processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of diseases or medical conditions mediated by cytokines.
    Type: Application
    Filed: April 5, 2011
    Publication date: January 5, 2012
    Applicant: AstraZeneca AB
    Inventors: Dearg Sutherland Brown, John Graham Cumming, Ian Alun Nash
  • Patent number: 8084452
    Abstract: The present application relates to novel substituted enaminocarbonyl compounds, to processes for their preparation and to their use for controlling animal pests, especially arthropods, in particular insects.
    Type: Grant
    Filed: March 19, 2007
    Date of Patent: December 27, 2011
    Assignee: Bayer Cropscience AG
    Inventors: Peter Jeschke, Robert Velten, Thomas Schenke, Otto Schallner, Michael Edmund Beck, Olga Malsam, Ralf Nauen, Thomas Müller, Christian Arnold, Erich Sanwald, Ulrich Görgens
  • Publication number: 20110294780
    Abstract: The present invention relates to compounds of Formula (I), methods for preparing these compounds, compositions, intermediates and derivatives thereof and for treating a condition including but not limited to ankylosing spondylitis, artherosclerosis, arthritis (such as rheumatoid arthritis, infectious arthritis, childhood arthritis, psoriatic arthritis, reactive arthritis), bone-related diseases (including those related to bone formation), breast cancer (including those unresponsive to anti-estrogen therapy), cardiovascular disorders, cartilage-related disease (such as cartilage injury/loss, cartilage degeneration, and those related to cartilage formation), chondrodysplasia, chondrosarcoma, chronic back injury, chronic bronchitis, chronic inflammatory airway disease, chronic obstructive pulmonary disease, diabetes, disorders of energy homeostasis, gout, pseudogout, lipid disorders, metabolic syndrome, multiple myeloma, obesity, osteoarthritis, osteogenesis imperfecta, osteolytic bone metastasis, osteomalac
    Type: Application
    Filed: May 24, 2011
    Publication date: December 1, 2011
    Inventors: Gilles Bignan, Wing Cheung, Micheal Gaul, Hui Huang, Xun Li, Raymond Patch, Sharmila Patel, Mark Player, Guozhang Xu, Bao-Ping Zhao, Jian Liu
  • Publication number: 20110294829
    Abstract: The present invention relates to hydroximoyl-heterocycle derivatives of formula (I) wherein T represents a substituted or non-substituted heterocyclyl group, Q represents a carbo or heterocyclic group, A represent a carbo or heterocyclic group or a carbo or hetero-polycylic group, and L1 represents various linking groups, their process of preparation, intermediate compounds for their preparation, their use as fungicide active agents, particularly in the form of fungicide compositions, and methods for the control of phytopathogenic fungi, notably of plants, using these compounds or compositions.
    Type: Application
    Filed: December 8, 2009
    Publication date: December 1, 2011
    Inventors: Christian Beier, Jurgen Benting, David Bernier, Pierre-Yves Coqueron, Philippe Desbordes, Christophe Dubost, Stephanie Gary, Pierre Genix, Daniela Portz, Ulrike Wachendorff-Neumann
  • Patent number: 8044053
    Abstract: The present invention relates to substituted pyrazoline compounds of general formula (I), methods for their preparation, medicaments comprising these compounds as well as their use for the preparation of a medicament for the treatment of humans and animals.
    Type: Grant
    Filed: October 10, 2007
    Date of Patent: October 25, 2011
    Assignee: Laboratories del Dr. Esteve, S.A.
    Inventors: Helmut Buschmann, Antonio Torrens-Jover, Josef Mas-Prio, Susana Yenes-Minguez
  • Publication number: 20110237783
    Abstract: Pharmaceutical compositions and compounds are provided. The compounds of the invention demonstrate anti-proliferative activity, and may promote apoptosis in cells lacking normal regulation of cell cycle and death. In one embodiment of the invention, pharmaceutical compositions of the compounds in combination with a physiologically acceptable carrier are provided. The pharmaceutical compositions are useful in the treatment of hyperproliferative disorders, which disorders include tumor growth, lymphoproliferative diseases, angiogenesis. The compounds of the invention are substituted pyrazoles and pyrazolines.
    Type: Application
    Filed: December 23, 2010
    Publication date: September 29, 2011
    Applicant: Valocor Therapeutics, Inc.
    Inventors: Zaihui Zhang, Timothy S. Daynard, Mikhail A. Chafeev, Shisen Wang, Gregory B. Chopiuk, Serguei V. Sviridov
  • Patent number: 8022079
    Abstract: Novel compounds having the general formula (I) below: are useful in a wide variety of applications in human or veterinary medicine (in dermatology, and also in the fields of cardiovascular diseases, immune diseases and/or diseases associated with lipid metabolism), or, alternatively are formulated into cosmetic compositions.
    Type: Grant
    Filed: September 18, 2009
    Date of Patent: September 20, 2011
    Assignee: Galderma Research & Development
    Inventors: Laurence Clary, Etienne Thoreau, Michel Rivier, Jerome Aubert, Laurent Chantalat, Johannes Voegel
  • Patent number: 8003675
    Abstract: A 3,4-dihalogenoisothiazole derivative represented by the general formula [I] (wherein R1 is a halogen atom; A is an oxygen atom or a sulfur atom; and R is a C1-C6 alkyl group, a C2-C5 alkenyl group, a C2-C5 alkynyl group, a C3-C6 cycloalkyl group, a phenyl group or a 5- to 10-membered heterocyclic group containing at least one of oxygen atom, sulfur atom and nitrogen atom), or a salt thereof.
    Type: Grant
    Filed: July 6, 2007
    Date of Patent: August 23, 2011
    Assignees: Kumiai Chemical Industry Co., Ltd., Ihara Chemical Industry Co., Ltd.
    Inventors: Toshihiro Nagata, Atsushi Kogure, Isao Kaneko, Norihisa Yonekura, Ryo Hanai
  • Publication number: 20110201777
    Abstract: Provided are a ?-electron conjugated polymer having a constitutional unit represented by general formula (2) that is suitable as an electrochromic material that changes from a desired colored state to a decolored state, a new compound that is a raw material of the polymer, and a method for producing the polymer: wherein each X independently represents one selected from the group consisting of an oxygen atom, a sulfur atom, —NH—, and —NR1— (wherein R1 is an optionally substituted alkyl group having 1 to 20 carbon atoms or an optionally substituted aryl group having 6 to 20 carbon atoms); each Y independently represents an oxygen atom or a sulfur atom; each Z independently represents one selected from the group consisting of a hydrogen atom and optionally substituted organic groups having 1 to 20 carbon atoms, and W is one selected from the group consisting of an ethynylene group, an optionally substituted ethenylene group, optionally substituted arylene groups, and optionally substituted divalent heteroaromati
    Type: Application
    Filed: October 16, 2009
    Publication date: August 18, 2011
    Applicant: KURARAY CO., LTD.
    Inventors: Yoshirou Kondou, Kirihiro Nakano, Tomiaki Otake
  • Patent number: 7968560
    Abstract: Novel compounds having the general formula (I) below: are useful in a wide variety of applications in human or veterinary medicine (in dermatology, and also in the fields of cardiovascular diseases, immune diseases and/or diseases associated with lipid metabolism), or, alternatively are formulated into cosmetic compositions.
    Type: Grant
    Filed: September 21, 2009
    Date of Patent: June 28, 2011
    Assignee: Galderma Research & Development
    Inventors: Laurence Clary, Etienne Thoreau, Michel Rivier, Jerome Aubert, Laurent Chantalat, Johannes Voegel
  • Publication number: 20110152234
    Abstract: The invention relates to thiophene carboxamides of formula (I), wherein A, R1, R2, R3, n and X are as defined in the specification, processes and intermediates used in their preparation, pharmaceutical compositions containing them and their use in therapy.
    Type: Application
    Filed: December 23, 2010
    Publication date: June 23, 2011
    Inventors: Alan Faull, Craig Johnstone, Andrew Morley, Jeffrey Philip Poyser
  • Patent number: 7842758
    Abstract: The invention concerns compounds, oligomers, and polymers that contain: (I), (II), (III), or (IV) groups; where “-” indicates points of attachment.
    Type: Grant
    Filed: January 10, 2007
    Date of Patent: November 30, 2010
    Assignee: The Trustees Of The University Of Pennsylvania
    Inventors: Michael J. Therien, Kimihiro Susumu
  • Publication number: 20100292187
    Abstract: The present invention provides compounds, pharmaceutical compositions, and methods of using such compounds or compositions for treating infection by a virus, or for affecting viral IRES activity.
    Type: Application
    Filed: June 14, 2010
    Publication date: November 18, 2010
    Applicant: PTC THERAPEUTICS, INC.
    Inventors: Gary M. Karp, Peter Seongwoo Hwang, James J. Takasugi, Hongyu Ren, Richard Gerald Wilde, Anthony A. Turpoff, Alexander Arefolov, Guangming Chen, Jeffrey A. Campbell, Chunshi Li, Steven Paget, Nanjing Zhang, Xiaoyan Zhang, Jin Zhu
  • Publication number: 20100273813
    Abstract: Novel N-phenylacetamide compounds of formula (I): and cosmetic and pharmaceutical compositions containing same are useful for treating disorders of the sebaceous gland, e.g., acne, or have cosmetic applications.
    Type: Application
    Filed: March 5, 2010
    Publication date: October 28, 2010
    Applicant: GALDERMA RESEARCH & DEVELOPMENT
    Inventor: Thibaud PORTAL
  • Publication number: 20100233116
    Abstract: The present invention provides heterocyclic derivatives hat modulate the activity of stearoyl-CoA desaturase. Methods of using such derivatives to modulate the activity of stearoyl-CoA desaturase and pharmaceutical compositions comprising such derivatives are also encompassed.
    Type: Application
    Filed: August 13, 2007
    Publication date: September 16, 2010
    Inventors: Natalie Dales, Julia Fonarev, Jianmin Fu, Rajender Kamboj, Vishnumurthy Kodumuru, Shifeng Liu, Natalia Pokrovskaia, Vandna Raina, Shaoyi Sun, Zaihui Zhang
  • Patent number: 7781431
    Abstract: The present invention relates to thienopyrrole compounds of formula (I); wherein A, B, Y, Ar, n, Z and X1 are as defined herein, and pharmaceutically acceptable salts thereof, useful in the prevention and treatment of hepatitis C infections.
    Type: Grant
    Filed: September 7, 2004
    Date of Patent: August 24, 2010
    Assignee: Istituto di Ricerche di Biologia Molecolare P Angeletti SpA
    Inventors: Barbara Attenni, Jose Ignacio Martin Hernando, Savina Malancona, Frank Narjes, Jesus Maria Ontoria Ontoria, Michael Rowley
  • Publication number: 20100197875
    Abstract: The present invention relates to white-emitting copolymers which are obtained by a combination of blue-, green- and red-emitting repeating units. The copolymers of the invention display better film formation and an improved efficiency when used in polymeric organic light-emitting diodes compared to materials according to the prior art.
    Type: Application
    Filed: March 22, 2010
    Publication date: August 5, 2010
    Applicant: Merck Patent GmbH
    Inventors: Aurelie Falcou, Arne Büsing, Susanne Heun, Jürgen Steiger, Anja Gerhard, Niels Schulte, Heinrich Becker
  • Patent number: 7763884
    Abstract: An organic semiconductor material represented by the following general formula (1): wherein X1 to X4 each independently represent a chalcogen atom; and at least one of R1 and R2 represents a substituent for obtaining solubility, and R1 and R2 may be connected to each other to form a ring.
    Type: Grant
    Filed: June 27, 2007
    Date of Patent: July 27, 2010
    Assignee: Sony Corporation
    Inventors: Mao Tatsuhara, Akito Ugawa
  • Patent number: 7737283
    Abstract: Novel compounds and methods of using those compounds for the treatment of inflammatory conditions are provided. In a preferred embodiment, modulation of the activation state of p38 kinase protein comprises the step of contacting the kinase protein with the novel compounds.
    Type: Grant
    Filed: June 9, 2006
    Date of Patent: June 15, 2010
    Assignee: Deciphera Pharmaceuticals, LLC
    Inventors: Daniel L. Flynn, Peter A. Petillo
  • Publication number: 20100119475
    Abstract: Compounds of general formula (I): wherein R1, R2, R3, R4, X and Y are as defined herein are inhibitors of glutaminyl cyclase and are therefore useful in treating conditions that can be treated by modulation of glutaminyl cyclase activity.
    Type: Application
    Filed: September 4, 2009
    Publication date: May 13, 2010
    Applicant: PROBIODRUG AG
    Inventors: Ulrich Heiser, Robert Sommer, Ulf-Torsten Gaertner, Antje Hamann, Michael Almstetter, Michael Thormann, Andreas Treml, Hans-Ulrich Demuth, Torsten Hoffman
  • Publication number: 20100069404
    Abstract: The present invention provides a compound of the formula: Formula (I) or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising a compound of Formula (I) in combination with a suitable carrier, diluent, or excipient; and methods for treating physiological disorders, particularly reduced bones mass, osteoporosis, osteopenia, or reduced muscle mass or strength, comprising administering a compound of Formula (I), or a pharmaceutically acceptable salt thereof. X-17142.
    Type: Application
    Filed: November 6, 2007
    Publication date: March 18, 2010
    Inventors: Konstantinos Gavardinas, Jonathan Edward Green, Prabhakar Kondaji Jadhav, Donald Paul Matthews
  • Patent number: 7652143
    Abstract: The present invention relates to a novel compound of the formula I: and/or all stereoisomeric forms of the compound of the formula I and/or mixtures of these forms in any ratio, and/or a physiologically tolerated salt of the compound of the formula I, in which R1 to R5 and V1, V2 have the meanings stated in the claims and specification. The inventive compounds are suitable as inhibitors of metalloproteases, especially of ADAMTS proteases and TNF-? converting enzyme (TACE), and for the treatment of disorders such as but not limited to osteoarthrosis and rheumatoid arthritis.
    Type: Grant
    Filed: June 15, 2007
    Date of Patent: January 26, 2010
    Assignee: sanofi-aventis Deutschland GmbH
    Inventors: Andreas Lindenschmidt, Holger Wagner, Jochen Beninga, Sven Grueneberg, Klaus-ulrich Weithmann
  • Publication number: 20090324511
    Abstract: Certain substituted urea derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure.
    Type: Application
    Filed: May 20, 2009
    Publication date: December 31, 2009
    Inventors: Bradley P. Morgan, Alex Muci, Erica Kraynack, Pu-Ping Lu, Todd Tochimoto, David J. Morgans, JR.
  • Patent number: 7632851
    Abstract: The present invention relates to novel benzo[1,2,5]oxadiazoles and benzo[1,2,5]thiadiazoles of formula (I) wherein X is O or S, R1 is 5-(2-fluoro-ethylamino)-thiazol-2-yl, 5-(2-18F-ethylamino)-thiazol-2-yl or a group of formula (a) wherein Y is CH or N, R2 is NHCH3, NH11CH3, N(CH3)11CH3, N(CH3)2, N(11CH3)2, NH(CH2)nF, NH(CH2)n18F, N(CH3)(CH2)nF, N(CH3)—(CH2)n18F, O—(CH2)nF, O—(CH2)n18F, CONH(CH2)nF or CONH(CH2)n18F (n being in each case 2 to 4) and R3 is hydroxy, (C1-4)alkoxy, hydrogen or nitro, in free base or acid addition salt form; their preparation, their use as markers in diagnosis and compositions containing them.
    Type: Grant
    Filed: April 2, 2004
    Date of Patent: December 15, 2009
    Assignee: Novartis AG
    Inventors: Yves Auberson, Samuel Hintermann, Kaspar Zimmermann
  • Publication number: 20090299072
    Abstract: Tetrasubstituted benzenes that act as modulators of gamma secretase and their use in the treatment of one or more symptoms of treating neurodegenerative disorders, e.g., Alzheimer's disease, are described.
    Type: Application
    Filed: December 22, 2008
    Publication date: December 3, 2009
    Inventors: Gideon Shapiro, Richard Chesworth
  • Patent number: 7625914
    Abstract: Novel compounds having the general formula (I) below: are useful in a wide variety of applications in human or veterinary medicine (in dermatology, and also in the fields of cardiovascular diseases, immune diseases and/or diseases associated with lipid metabolism), or, alternatively are formulated into cosmetic compositions.
    Type: Grant
    Filed: December 20, 2005
    Date of Patent: December 1, 2009
    Assignee: Galderma Research & Development
    Inventors: Laurence Clary, Etienne Thoreau, Michel Rivier, Jerome Aubert, Laurent Chantalat, Johannes Voegel